Issam Raad
Affiliations: | The University of Texas School of Public Health |
Area:
Public HealthGoogle:
"Issam Raad"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Haddad A, Wilson Dib R, Chaftari AM, et al. (2025) Risk factors for catheter-related bloodstream infections in a high-risk cancer patient population. Infection Control and Hospital Epidemiology. 1-4 |
| Dagher H, Chaftari AM, Hachem R, et al. (2024) Procalcitonin Level Monitoring in Antibiotic De-Escalation and Stewardship Program for Patients with Cancer and Febrile Neutropenia. Cancers. 16 |
| Chaftari AM, Dagher H, Hachem R, et al. (2024) A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia. The Journal of Antimicrobial Chemotherapy |
| Haddad AJ, Hachem RY, Moussa M, et al. (2024) Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients. Cancers. 16 |
| Gerges B, Rosenblatt J, Shellburne SA, et al. (2023) activity of tebipenem and comparator agents against bacterial pathogens isolated from patients with cancer. Jac-Antimicrobial Resistance. 5: dlad132 |
| Gerges B, Rolston K, Shelburne SA, et al. (2023) The activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer. Jac-Antimicrobial Resistance. 5: dlad034 |
| Rolston K, Gerges B, Nesher L, et al. (2023) activity of eravacycline and comparator agents against bacterial pathogens isolated from patients with cancer. Jac-Antimicrobial Resistance. 5: dlad020 |
| Dagher H, Chaftari AM, Subbiah IM, et al. (2023) Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period. Elife. 12 |
| Raad II, Hachem R, Masayuki N, et al. (2023) International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: impact of risk factors and treatment modalities on survivorship. Elife. 12 |
| Dagher H, Chaftari AM, Mulanovich P, et al. (2022) Procalcitonin for antimicrobial stewardship among cancer patients admitted with COVID-19. Elife. 11 |